These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9807055)

  • 1. Use of angiotensin-converting enzyme inhibitors in patients with diabetic and nondiabetic chronic renal diseases: a need for reassessment.
    Jaichenko J; Fudin R; Shostak A; Gotloib L
    Nephron; 1998 Nov; 80(3):367-8. PubMed ID: 9807055
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin converting enzyme inhibitors: the end of end-stage renal disease?
    Feig PU; Rutan GH
    Ann Intern Med; 1989 Sep; 111(6):451-3. PubMed ID: 2672924
    [No Abstract]   [Full Text] [Related]  

  • 3. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate.
    Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
    Diabetes Metab Syndr; 2012; 6(4):215-7. PubMed ID: 23199543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical use of angiotensin-converting enzyme inhibitors in patients with renal impairment.
    Elliott HL
    Blood Press Suppl; 1994; 2():31-4. PubMed ID: 8061843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [ACE inhibitors and kidney].
    Ritz E
    Wien Med Wochenschr; 1990 Jan; 140(1-2):18-21. PubMed ID: 2408246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ace inhibition in renal disease: risks and benefits.
    Campanacci L; Fabris B; Fischetti F; Bardelli M; Vran F; Carretta R
    Clin Exp Hypertens; 1993; 15 Suppl 1():173-86. PubMed ID: 8513308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission of renal disease: recounting the challenge, acquiring the goal.
    Brenner BM
    J Clin Invest; 2002 Dec; 110(12):1753-8. PubMed ID: 12488422
    [No Abstract]   [Full Text] [Related]  

  • 9. [Progression of chronic renal insufficiency and its prevention using angiotensin converting enzyme inhibitors and angiotensin antagonists].
    Tesar V
    Vnitr Lek; 2003 May; 49(5):365-9. PubMed ID: 12908169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In patients with chronic diabetic nephropathy, do angiotensin-converting enzyme inhibitors (ACEI) have greater renal protective effect as compared to angiotensin receptor blockers (ARB)?
    Tucker S; Chen Y; Abell R
    J Okla State Med Assoc; 2013 Jul; 106(7):294-5. PubMed ID: 24032256
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of angiotensin-converting-enzyme inhibitors in the management of renal disease.
    Asher JP; Murray KM
    Clin Pharm; 1991 Jan; 10(1):25-31. PubMed ID: 1999085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Protective effect of antihypertensive agents on renal insufficiency (REIN, RENAAL, IDNT, AASK, etc)].
    Tsuchida H; Kimura K
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():617-22. PubMed ID: 15171445
    [No Abstract]   [Full Text] [Related]  

  • 14. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of primary physicians in the early detection and treatment of chronic renal disease: challenges and opportunities].
    Cueto-Manzano AM
    Rev Invest Clin; 2008; 60(6):517-26. PubMed ID: 19378838
    [No Abstract]   [Full Text] [Related]  

  • 16. Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway?
    Yilmaz MI; Sonmez A; Saglam M; Yaman H; Cayci T; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Yenicesu M; Axelsson J
    Nephrol Dial Transplant; 2010 Oct; 25(10):3250-6. PubMed ID: 20348148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease.
    Adarkwah CC; Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Apr; 11(2):215-23. PubMed ID: 21476823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Uses of angiotensin converting enzyme inhibitor in kidney diseases].
    Xu XW; Wang HY
    Zhonghua Yi Xue Za Zhi; 1995 Feb; 75(2):122-4. PubMed ID: 7767767
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.
    Nakao N; Yoshimura A; Morita H; Takada M; Kayano T; Ideura T
    Lancet; 2003 Jan; 361(9352):117-24. PubMed ID: 12531578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers.
    Berl T
    Nephrol Dial Transplant; 2008 Aug; 23(8):2443-7. PubMed ID: 18467376
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.